Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches

Abstract

Acute kidney injury (AKI) presents as a condition marked by a sudden and rapid decrease in kidney function over a short timeframe, resulting from diverse causes. As a transcription factor, PR domain‐containing 16 (PRDM16), has recently been implicated in brown fat biogenesis and heart diseases. Our recent works indicated that PRDM16 could suppress the occurrence of renal interstitial fibrosis in diabetic kidney disorder. Nonetheless, the effect and regulatory mechanism of PRDM16 in AKI remain elusive. Our study demonstrated that PRDM16 inhibited apoptosis induced by ischemic/reperfusion (I/R) in BUMPT (Boston University mouse kidney proximal tubular) cells and HK‐2(Human Kidney‐2) cells. Mechanistically, PRDM16 not only bound to the promoter region of S100 Calcium Binding Protein A6 (S100A6)and upregulated its expression but also interacted with its amino acids 945–949, 957–960, and 981–984 to suppress the p38MAPK and JNK axes via inhibition of PKC‐η activity and mitochondrial reactive oxygen species (ROS) production. Furthermore, cisplatin‐ and I/R‐stimulated AKI progression were ameliorated in PRDM16 proximal‐tubule‐specific knockin mice, whereas exacerbated in PRDM16 knockout proximal‐tubule‐specific mice). Moreover, we observed that formononetin ameliorated I/R‐ and cisplatin‐triggered AKI progression in mice. Taken together, these findings reveal a novel self‐protective mechanism in AKI, whereby PRDM16 regulates the S100A6/PKC‐η/ROS/p38MAPK and JNK pathways to inhibit AKI progression.